Loading
The PRECEDE consortium set out how the field should organise itself to detect pancreatic cancer early: shared enrolment criteria, a common data and biospecimen registry, and international collaboration rather than isolated single-centre cohorts.
The Pancreatic Cancer Early Detection consortium published recommendations for a more organised and effective approach to early detection of pancreatic cancer, covering the coordination of high-risk cohorts, standardised data collection and biospecimen banking across centres.
PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.
Shares Diane M. Simeone, PRECEDE, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, High-risk pancreatic surveillance (CAPS / PRECEDE).
Shares PRECEDE, Gastroenterology, High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
Shares Diane M. Simeone, PRECEDE, High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
Shares Gastroenterology, Liquid biopsy (ctDNA), Pancreatic ductal adenocarcinoma.
Shares Gastroenterology, High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
Shares PRECEDE, High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.